Guideline No. 444: Hirsutism: Evaluation and Treatment

医学 指南 多毛症 梅德林 妇科 医学物理学 内科学 病理 政治学 法学 胰岛素抵抗 胰岛素 多囊卵巢
作者
Jason Elliott,Kimberly Liu,Tarek Motan
出处
期刊:Journal of obstetrics and gynaecology Canada [Elsevier BV]
卷期号:45 (12): 102272-102272
标识
DOI:10.1016/j.jogc.2023.102272
摘要

Abstract

Objective

This guideline reviews the etiology, diagnosis, evaluation, and treatment of hirsutism.

Target Population

Women with hirsutism.

Options

Three approaches to management include: 1) mechanical hair removal; 2) suppression of androgen production; and 3) androgen receptor blockade.

Outcomes

The main limitations of the management options include the adverse effects, costs, and duration of treatment.

Benefits, Harms, and Costs

Implementation of the recommendations in this guideline may improve the management of hirsutism in women with this condition. Adverse effects and a potential long duration of treatment are the main drawbacks to initiating treatment, as is the possibility of significant financial costs for certain treatments.

Evidence

A comprehensive literature review was updated to April 2022, following the same methods as for the prior Society of Obstetricians and Gynaecologists of Canada (SOGC) Hirsutism guidelines. Results were restricted to systematic reviews, randomized controlled trials, controlled clinical trials, and observational studies. There were no date limits, but results were limited to English- or French-language materials.

Validation Methods

The authors rated the quality of evidence and strength of recommendations using the modified Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach, along with the option of designating a recommendation as a "good practice point." See online Appendix A (Tables A1 for definitions and A2 for interpretations of strong and conditional [weak] recommendations).

Intended Audience

Primary care providers, family medicine physicians, obstetricians and gynaecologists, reproductive endocrinologists and others who manage the care of patients with hirsutism.

Tweetable Abstract

Management of hirsutism involves a 3-pronged approach of mechanical hair removal, suppression of androgen production, and androgen receptor blockade.

SUMMARY STATEMENTS

  • 1.The modified Ferriman-Gallwey score can be used in the assessment of hirsutism to help quantify the problem and assess the response to treatment. Cut-off scores defining hirsutism will vary by racial background. Modified Ferriman-Gallwey scores from 3 to 15 represent mild hirsutism, 16–25 represent moderate hirsutism, and >25 indicate severe hirsutism (moderate).
  • 2.Hyperandrogenism in women with polycystic ovary syndrome may result from several mechanisms, including insulin resistance, hyperinsulinemia, elevated luteinizing hormone–related increases in theca cell androgen production, and increased adrenal androgen output. (high).
  • 3.Non-classical congenital adrenal hyperplasia often presents with hirsutism and has a similar clinical picture as polycystic ovary syndrome. However, the prevalence of non-classical congenital adrenal hyperplasia is very low outside of specific high-risk ethnic groups (high).
  • 4.Hirsutism can be classified into 1 of 3 groups based on etiology: hyperandrogenic hirsutism (including polycystic ovarian syndrome, non-classical congenital adrenal hyperplasia, or androgen-secreting tumours), non-androgenic hirsutism (including medication-induced hirsutism), and idiopathic hirsutism (moderate).
  • 5.Polycystic ovary syndrome is the most common cause of hirsutism, with idiopathic hirsutism being the second most common (high).
  • 6.Most patients with hirsutism have normal androgen levels. That said, high androgen levels should be investigated immediately, as some impacts will be permanent, such as voice changes and clitoromegaly (high).
  • 7.Hirsutism is not a diagnosis, but a symptom or sign, and an underlying etiology should be sought (high).
  • 8.The most effective therapy for hirsutism is multimodal and combines physical hair removal techniques with medical therapies. At least six months of medical therapy is required to see a significant improvement in hirsutism. Unfortunately, many permanent physical hair removal procedures are considered cosmetic and the costs can be a barrier to treatment (moderate).
  • 9.Hair growth tends to recur after stopping medical therapy, while laser hair removal, intense pulsed light, and electrolysis produce permanent hair reduction (moderate).

RECOMMENDATIONS

  • 1.Patients presenting with hirsutism should be evaluated with a focused history taking, physical examination with anthropometric measurements, and appropriate investigations to differentiate between the possible etiologies (strong, moderate).
  • 2.Patients with moderate to severe hirsutism should undergo blood testing to determine total testosterone and sex hormone–binding globulin levels; however, the benefit of testing in mild hirsutism is questionable. Additional testing is indicated for patients with irregular cycles and signs of hyperandrogenism or other endocrinopathies (conditional, low).
  • 3.Patients with hyperandrogenic hirsutism should have serum levels of dehydroepiandrosterone sulfate and 17-hydroxyprogesterone measured (strong, moderate).
  • 4.Referral for evaluation by a medical or reproductive endocrinologist (or another practitioner with similar expertise) is indicated in the presence of 1) virilization; 2) serum testosterone or dehydroepiandrosterone sulfate levels more than twice the upper limit of normal; 3) signs or symptoms of Cushing syndrome; or 4) early follicular phase serum 17-hydroxyprogesterone levels >6 nmol/L (strong, high).
  • 5.Therapy should be offered to all patients with hirsutism who desire treatment (good practice point).
  • 6.Combined hormonal contraceptives should be offered as first-line therapy if there are no contraindications (strong, high).
  • 7.Mechanical hair removal and/or topical treatments can be offered as first-line therapy or as an adjuvant to medical therapy (strong, high).
  • 8.Antiandrogens can be considered as monotherapy or in addition to combined hormonal contraceptives to enhance efficacy (strong, high).
  • 9.Patients on antiandrogens require an effective method of contraception and should be counselled regarding the risk of feminization of a male fetus if pregnancy were to occur (good practice point).
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
优雅的雁凡完成签到,获得积分10
刚刚
文静静静完成签到 ,获得积分10
刚刚
shijin135完成签到,获得积分10
1秒前
彪壮的绮烟完成签到,获得积分10
2秒前
grs完成签到,获得积分10
2秒前
dis完成签到,获得积分10
3秒前
刘雅彪完成签到 ,获得积分10
3秒前
正经大善人完成签到,获得积分10
4秒前
英俊的铭应助医学小王采纳,获得10
4秒前
4秒前
芝儿完成签到 ,获得积分10
5秒前
5秒前
gaoxiaogao完成签到,获得积分10
5秒前
在水一方应助Rae采纳,获得10
6秒前
耍酷的翠曼完成签到,获得积分10
7秒前
司徒乌完成签到,获得积分10
7秒前
thisky完成签到,获得积分10
8秒前
lilian发布了新的文献求助10
8秒前
DyLan完成签到,获得积分0
8秒前
共享精神应助明明明采纳,获得10
9秒前
渴望者完成签到,获得积分20
9秒前
9秒前
默然的歌完成签到 ,获得积分10
9秒前
星星完成签到,获得积分10
9秒前
David完成签到 ,获得积分10
9秒前
Evan123完成签到,获得积分10
10秒前
空格TNT完成签到 ,获得积分10
11秒前
JIE发布了新的文献求助10
12秒前
小彭完成签到,获得积分10
13秒前
13秒前
Akim应助超帅含烟采纳,获得10
13秒前
Oo。完成签到,获得积分10
13秒前
14秒前
香蕉觅云应助joy采纳,获得10
14秒前
Shark完成签到,获得积分10
14秒前
刻苦小丸子完成签到,获得积分10
14秒前
左丘冬寒完成签到,获得积分10
14秒前
于晓雅完成签到,获得积分10
15秒前
16秒前
Hou完成签到,获得积分10
17秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
Cognitive Neuroscience: The Biology of the Mind 1000
Technical Brochure TB 814: LPIT applications in HV gas insulated switchgear 1000
Immigrant Incorporation in East Asian Democracies 600
Nucleophilic substitution in azasydnone-modified dinitroanisoles 500
不知道标题是什么 500
A Preliminary Study on Correlation Between Independent Components of Facial Thermal Images and Subjective Assessment of Chronic Stress 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3968603
求助须知:如何正确求助?哪些是违规求助? 3513420
关于积分的说明 11168029
捐赠科研通 3248900
什么是DOI,文献DOI怎么找? 1794540
邀请新用户注册赠送积分活动 875187
科研通“疑难数据库(出版商)”最低求助积分说明 804676